Market Research Logo

Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016

Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016’, provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted pipeline therapeutics.

The report provides comprehensive information on the Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1)
  • The report reviews Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Overview
Therapeutics Development
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Stage of Development
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Therapy Area
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Indication
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Companies
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Universities/Institutes
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Companies Involved in Therapeutics Development
AnaBios Corporation
Astellas Pharma Inc.
AstraZeneca Plc
Flex Pharma, Inc.
Glenmark Pharmaceuticals Ltd.
Hydra Biosciences, Inc.
Johnson & Johnson
Pila Pharma AB
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Drug Profiles
ASP-7663 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-465 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-787 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRC-17536 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydralazine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-41477670 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block TRPA1 and TRPV1 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block TRPA1 and TRPV1 for Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Dormant Projects
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Discontinued Products
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Featured News & Press Releases
Jun 15, 2016: Flex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis
May 25, 2016: Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps
Apr 19, 2016: Flex Pharma’s Positive Human NLC Study Selected for Presentation at AAN Annual Meeting
Mar 14, 2016: Flex Pharma Positive Human NLC Study Selected for Late-Breaking Presentation at AAN Annual Meeting
Feb 02, 2016: Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study
Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11
Jan 06, 2016: Enrollment Completed in Flex Pharma’s Exploratory Human Nocturnal Leg Cramp Study
Nov 10, 2015: Flex Pharma Announces FLX-787 as Clinical Drug Candidate
Oct 20, 2015: Flex Pharma Demonstrates Single Agent Efficacy and Dose Response in Reducing Human Muscle Cramps
Jul 28, 2015: Flex Pharma Announces Two Poster Presentations at Upcoming Scientific Meetings
Jul 07, 2015: Flex Pharma Announces Reduction of Muscle Cramping in Athletes
May 04, 2015: NSF Approves Flex Pharma’s Proprietary Formulation under NSF’s Certified for Sport Program
Apr 27, 2015: Flex Pharma Initiates Human Proof-of-Concept Efficacy Study in Nocturnal Leg Cramps
Apr 14, 2015: Hydra Biosciences Receives Approval from Health Canada to Begin Phase 1 Trial for HX-100
Feb 18, 2015: AAN Selects Flex Pharma Data for Oral Platform Presentation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by AnaBios Corporation, H2 2016
Pipeline by Astellas Pharma Inc., H2 2016
Pipeline by AstraZeneca Plc, H2 2016
Pipeline by Flex Pharma, Inc., H2 2016
Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
Pipeline by Hydra Biosciences, Inc., H2 2016
Pipeline by Johnson & Johnson, H2 2016
Pipeline by Pila Pharma AB, H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report